609-92-7

Upstream product

• 106-42-3 para-xylene 
• 89-58-7 mononitro-p-xylene 
• 7697-37-2 nitric acid 
• 6311-52-0 3,6-dimethyl-2,4-dinitro-aniline 

Downstream Products

• 62564-50-5 2,5-dimethyl-3-nitroaniline 
• 51136-52-8 2,6-diamino-p-xylene 
• 69824-99-3 3,5-dinitrobenzene-1,4-dioic acid 
• 880086-94-2 ethyl 2,5-dimethyl-3-nitrophenylimidoformate 
• 880086-93-1 6-methyl-4-nitro-1H-indole 
• 90764-89-9 6-methyl-1H-indazol-4-amine 
• 90086-91-2 3-Amino-2,5-dimethyl-phenol 
• 65151-57-7 3-nitro-2,5-dimethylphenol 
• 35111-99-0 2,6-dinitro-terephthalic acid-4-ethyl ester 

Relevant academic research and scientific papers

X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson’s Disease

Human indoleamine 2,3-dioxygenase 1 (hIDO1) and tryptophan 2,3-dioxygenase (hTDO) have been closely linked to the pathogenesis of Parkinson’s disease (PD); nevertheless, development of dual hIDO1 and hTDO inhibitors to evaluate their potential efficacy against PD is still lacking. Here, we report biochemical, biophysical, and computational analyses revealing that 1H-indazole-4-amines inhibit both hIDO1 and hTDO by a mechanism involving direct coordination with the heme ferrous and ferric states. Crystal structure-guided optimization led to23, which manifested IC50values of 0.64 and 0.04 μM to hIDO1 and hTDO, respectively, and had good pharmacokinetic properties and brain penetration in mice.23showed efficacy against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse motor coordination deficits, comparable to Madopar, an anti-PD medicine. Further studies revealed that different from Madopar,23likely has specific anti-PD mechanisms involving lowering IDO1 expression, alleviating dopaminergic neurodegeneration, reducing inflammatory cytokines and quinolinic acid in mouse brain, and increasing kynurenic acid in mouse blood.

Nitration of deactivated aromatic compounds via mechanochemical reaction

A variety of deactivated arenes were nitrated to their corresponding nitro derivatives in excellent yields under high-speed ball milling condition using Fe(NO3)3·9H2O/P2O5 as nitrating reagent. A radical involved mechanism was proposed for this facial, eco-friendly, safe, and effective nitration reaction.

Method for synthesizing 2,6-dinitroterephthalic acid (by machine translation)

The reaction solution is subjected to post-treatment 2,6 - to obtain,dinitroterephthalic acid: and then the reaction solution is heated to, for, minutes, and then the reaction solution is heated to a reflux reaction 30 °C for, hours after the reaction sys

Method for preparing 1H-indazole derivative

The invention discloses a method for preparing a 1H-indazole derivative. The method takes a compound as a formula (A1) or a compound as a formula (A2) as raw materials, and the compound as the formula(A1) and the compound as the formula (A2) are subjected

TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

SPIROLACTAM TRICYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula (I): (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, J, K, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

SPIROHYDANTOIN TRICYCLIC CGRP RECEPTOR ANTAGONISTS

Compounds of formula I: (wherein variables A1, A2, A3, A4, A5, A6, A7, B1, B2, B3, B4, D1, D2, E1, E2, E3, E4, E5, G1, G2, R6, T, U, V, W, X, Y and Z are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

TRICYCLIC ANILIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, T, U, V, W, X, Y, Z, R4, R5a?, R5b/su

TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS

The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, J, K, T, U, V, W, X, Y, Z, R4, R5a, R5b, R5c, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

Synthesis and characterization of Nitro-p-xylenes

In this paper we elected to nitrate p-xylene because this compound has only one mononitro- and trinitro- isomer. Trinitro-p-xylene was used as a starting material for the synthesis of other compounds in subsequent work. The mononitration of p-xylene can be easily carried out at 30°C. Nitro-p-xylene is easily nitrated to dinitro-p-xylene at a temperature of 80°C. The trinitro-p-xylene can be obtained at 120°C. Single crystals of 2,3-dinitro-p-xylene and 2,3,5-trinitro-p-xylene were grown using the slow cooling method and we report the X-ray structure of the former. The thermal decomposition of the compounds was studied using differential scanning calorimetry (DSC) and thermogravimetry-derivative thermogravimetry (TG-DTG) techniques and FT-IR. The target compounds were also characterized by 1H-NMR, 13C-NMR and MS.